Management and Prevention of Paramyxoviruses in Hematopoietic Cell Transplantation Recipients

This session covered the latest guidelines for managing respiratory syncytial virus (RSV) and other paramyxoviruses, focusing on epidemiology, clinical diagnosis, prophylaxis, and treatment strategies. Experts will discuss special considerations for pediatric, cord blood, haploidentical, and T cell-depleted HCT patients, as well as chimeric antigen receptor T cell therapy recipients. Review the recently published guidelines here.

Learning Objectives:

• Analyze the epidemiological patterns and risk factors of paramyxovirus infections in hematopoietic cell transplantation (HCT) recipients.
• Evaluate and differentiate the key clinical features for the paramyxoviruses hMPV and PIV in HCT patients.
• Apply current prophylaxis and treatment strategies for paramyxovirus infections in HCT recipients, comparing their effectiveness and potential outcomes.
• Synthesize special considerations for paramyxovirus management in specific HCT patient populations, integrating various factors that influence treatment decisions

Panelists:

• Marjorie Vieira Batista, MD, TID, PhD, ACCamargo Cancer Center
• Alpana Waghmare, MD, Department of Pediatrics, University of Washington School of Medicine

Moderators:

• Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, Department of Infectious Diseases, MD Anderson Cancer Center
• Diego R Hijano, MD, MSc, St. Jude Children's Research

The American Society for Transplantation and Cellular Therapy (ASTCT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The American Society for Transplantation and Cellular Therapy (ASTCT) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Disclosures